Mark Elliott Boulding - 02 Jan 2026 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
EXEC. VP AND CLO
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Issuer symbol
PTCT
Transactions as of
02 Jan 2026
Net transactions value
-$81,866
Form type
4
Filing time
06 Jan 2026, 17:20:26 UTC
Previous filing
19 Nov 2025
Next filing
08 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boulding Mark Elliott EXEC. VP AND CLO C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN /s/ Avraham S. Adler, Attorney-in-Fact 06 Jan 2026 0001578852

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Award $0 +17,000 +16% $0.000000 120,901 02 Jan 2026 Direct F1
transaction PTCT Common Stock Options Exercise $89,326 +2,266 +1.9% $39.42 123,167 05 Jan 2026 Direct F2
transaction PTCT Common Stock Sale $84,135 -1,123 -0.91% $74.92 122,044 05 Jan 2026 Direct F2, F3
transaction PTCT Common Stock Sale $78,764 -1,035 -0.85% $76.10 121,009 05 Jan 2026 Direct F2, F4
transaction PTCT Common Stock Sale $8,293 -108 -0.09% $76.79 120,901 05 Jan 2026 Direct F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Award $0 +42,500 $0.000000 42,500 02 Jan 2026 Common Stock 42,500 $76.74 Direct F6
transaction PTCT Stock Option (Right to Buy) Options Exercise $0 -2,266 -20% $0.000000 9,063 05 Jan 2026 Common Stock 2,266 $39.42 Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.
F2 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.
F3 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $74.55 to $75.27 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.58 to $76.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.75 to $76.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F6 This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.
F7 This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.